These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 18413374)

  • 41. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions.
    Antoniou AC; Cunningham AP; Peto J; Evans DG; Lalloo F; Narod SA; Risch HA; Eyfjord JE; Hopper JL; Southey MC; Olsson H; Johannsson O; Borg A; Pasini B; Radice P; Manoukian S; Eccles DM; Tang N; Olah E; Anton-Culver H; Warner E; Lubinski J; Gronwald J; Gorski B; Tryggvadottir L; Syrjakoski K; Kallioniemi OP; Eerola H; Nevanlinna H; Pharoah PD; Easton DF
    Br J Cancer; 2008 Apr; 98(8):1457-66. PubMed ID: 18349832
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Counseling the at risk patient in the BRCA1 and BRCA2 Era.
    Barnes-Kedar IM; Plon SE
    Obstet Gynecol Clin North Am; 2002 Jun; 29(2):341-66, vii. PubMed ID: 12108833
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer.
    Antonucci I; Provenzano M; Sorino L; Balsamo M; Aceto GM; Battista P; Euhus D; Cianchetti E; Ballerini P; Natoli C; Palka G; Stuppia L
    J Hum Genet; 2017 Mar; 62(3):379-387. PubMed ID: 27928164
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of PENN II model to previous study.
    Lindor NM; Johnson KJ; Harvey H; Shane Pankratz V; Domchek SM; Hunt K; Wilson M; Cathie Smith M; Couch F
    Fam Cancer; 2010 Dec; 9(4):495-502. PubMed ID: 20512419
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing.
    de la Hoya M; Osorio A; Godino J; Sulleiro S; Tosar A; Perez-Segura P; Fernandez C; Rodríguez R; Díaz-Rubio E; Benítez J; Devilee P; Caldés T
    Int J Cancer; 2002 Feb; 97(4):466-71. PubMed ID: 11802208
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO.
    Bonadona V; Sinilnikova OM; Lenoir GM; Lasset C
    J Natl Cancer Inst; 2002 Oct; 94(20):1582-3; author reply 1583-4. PubMed ID: 12381714
    [No Abstract]   [Full Text] [Related]  

  • 47. Optimal selection of individuals for BRCA mutation testing: a comparison of available methods.
    James PA; Doherty R; Harris M; Mukesh BN; Milner A; Young MA; Scott C
    J Clin Oncol; 2006 Feb; 24(4):707-15. PubMed ID: 16446345
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history.
    Gómez García EB; Oosterwijk JC; Timmermans M; van Asperen CJ; Hogervorst FB; Hoogerbrugge N; Oldenburg R; Verhoef S; Dommering CJ; Ausems MG; van Os TA; van der Hout AH; Ligtenberg M; van den Ouweland A; van der Luijt RB; Wijnen JT; Gille JJ; Lindsey PJ; Devilee P; Blok MJ; Vreeswijk MP
    Breast Cancer Res; 2009; 11(1):R8. PubMed ID: 19200354
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2.
    Gabai-Kapara E; Lahad A; Kaufman B; Friedman E; Segev S; Renbaum P; Beeri R; Gal M; Grinshpun-Cohen J; Djemal K; Mandell JB; Lee MK; Beller U; Catane R; King MC; Levy-Lahad E
    Proc Natl Acad Sci U S A; 2014 Sep; 111(39):14205-10. PubMed ID: 25192939
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of the BOADICEA risk assessment model in women with a family history of breast cancer.
    Ståhlbom AK; Johansson H; Liljegren A; von Wachenfeldt A; Arver B
    Fam Cancer; 2012 Mar; 11(1):33-40. PubMed ID: 22124624
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO.
    Biswas S; Tankhiwale N; Blackford A; Barrera AM; Ready K; Lu K; Amos CI; Parmigiani G; Arun B
    Breast Cancer Res Treat; 2012 May; 133(1):347-55. PubMed ID: 22270937
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Validation of the Manchester scoring system for predicting BRCA1/2 mutations in 9,390 families suspected of having hereditary breast and ovarian cancer.
    Kast K; Schmutzler RK; Rhiem K; Kiechle M; Fischer C; Niederacher D; Arnold N; Grimm T; Speiser D; Schlegelberger B; Varga D; Horvath J; Beer M; Briest S; Meindl A; Engel C
    Int J Cancer; 2014 Nov; 135(10):2352-61. PubMed ID: 24700448
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Improving the accuracy of BRCA1/2 mutation prediction: validation of the novel country-customized IC software.
    Capalbo C; Ricevuto E; Vestri A; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A; Giannini G
    Eur J Hum Genet; 2006 Jan; 14(1):49-54. PubMed ID: 16288312
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Estimate of the penetrance of BRCA mutation and the COS software for the assessment of BRCA mutation probability.
    Berrino J; Berrino F; Francisci S; Peissel B; Azzollini J; Pensotti V; Radice P; Pasanisi P; Manoukian S
    Fam Cancer; 2015 Mar; 14(1):117-28. PubMed ID: 25373702
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Genetic testing in Poland and Ukraine: should comprehensive germline testing of
    Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A
    Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 57. BRCAPRO 6.0 Model Validation in Male Patients Presenting for BRCA Testing.
    Mitri ZI; Jackson M; Garby C; Song J; Giordano SH; Hortobágyi GN; Singletary CN; Hashmi SS; Arun BK; Litton JK
    Oncologist; 2015 Jun; 20(6):593-7. PubMed ID: 25948675
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Multigene panel testing in unselected Israeli breast cancer cases: mutational spectrum and use of BRCA1/2 mutation prediction algorithms.
    Bernstein-Molho R; Singer A; Laitman Y; Netzer I; Zalmanoviz S; Friedman E
    Breast Cancer Res Treat; 2019 Jul; 176(1):165-170. PubMed ID: 30980208
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pathology update to the Manchester Scoring System based on testing in over 4000 families.
    Evans DG; Harkness EF; Plaskocinska I; Wallace AJ; Clancy T; Woodward ER; Howell TA; Tischkowitz M; Lalloo F
    J Med Genet; 2017 Oct; 54(10):674-681. PubMed ID: 28490612
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk Prediction Tools Available for Germline BRCA1/2 Mutations Underperform in Prostate Cancer Patients.
    Oliva L; Lozano R; Llácer C; Aragón I; Pajares BI; Sáez MI; Herrera-Imbroda B; Montesa A; Hernández D; Villatoro R; Otero A; Correa R; Grau G; Peinado P; Pacheco MI; García-Galisteo E; Rueda A; Machuca FJ; Alba E; Márquez-Aragonés A; Olmos D; Castro E
    Eur Urol Oncol; 2021 Apr; 4(2):315-318. PubMed ID: 31307957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.